nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—breast cancer—ovarian cancer	0.397	1	CtDrD
Lapatinib—ERBB2—ovarian cancer	0.183	0.618	CbGaD
Lapatinib—EGFR—ovarian cancer	0.0865	0.293	CbGaD
Lapatinib—EGFR—Docetaxel—ovarian cancer	0.0647	0.478	CbGbCtD
Lapatinib—ABCB1—ovarian cancer	0.0263	0.0889	CbGaD
Lapatinib—ABCB1—Topotecan—ovarian cancer	0.0108	0.0796	CbGbCtD
Lapatinib—CYP3A5—Paclitaxel—ovarian cancer	0.00819	0.0605	CbGbCtD
Lapatinib—CYP2C8—Paclitaxel—ovarian cancer	0.00788	0.0582	CbGbCtD
Lapatinib—ABCB1—Vinorelbine—ovarian cancer	0.00759	0.0561	CbGbCtD
Lapatinib—CYP3A4—Topotecan—ovarian cancer	0.00645	0.0477	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—ovarian cancer	0.00592	0.0437	CbGbCtD
Lapatinib—ABCB1—Paclitaxel—ovarian cancer	0.00533	0.0394	CbGbCtD
Lapatinib—CYP3A4—Vinorelbine—ovarian cancer	0.00455	0.0336	CbGbCtD
Lapatinib—ABCB1—Docetaxel—ovarian cancer	0.00386	0.0285	CbGbCtD
Lapatinib—CYP3A4—Paclitaxel—ovarian cancer	0.00319	0.0236	CbGbCtD
Lapatinib—ERBB2—oviduct—ovarian cancer	0.00297	0.0771	CbGeAlD
Lapatinib—ABCB1—Doxorubicin—ovarian cancer	0.00287	0.0212	CbGbCtD
Lapatinib—CYP3A4—Docetaxel—ovarian cancer	0.00231	0.0171	CbGbCtD
Lapatinib—CYP3A4—Doxorubicin—ovarian cancer	0.00172	0.0127	CbGbCtD
Lapatinib—TAP1—myometrium—ovarian cancer	0.0013	0.0338	CbGeAlD
Lapatinib—PIK3C2B—myometrium—ovarian cancer	0.00122	0.0317	CbGeAlD
Lapatinib—Gefitinib—CHEK2—ovarian cancer	0.00111	0.657	CrCbGaD
Lapatinib—TAP1—uterine cervix—ovarian cancer	0.00101	0.0263	CbGeAlD
Lapatinib—TAP1—decidua—ovarian cancer	0.000965	0.025	CbGeAlD
Lapatinib—PIK3C2B—uterine cervix—ovarian cancer	0.000951	0.0247	CbGeAlD
Lapatinib—TAP1—endometrium—ovarian cancer	0.000916	0.0238	CbGeAlD
Lapatinib—ERBB2—embryo—ovarian cancer	0.000914	0.0237	CbGeAlD
Lapatinib—ERBB4—embryo—ovarian cancer	0.000914	0.0237	CbGeAlD
Lapatinib—PIK3C2B—decidua—ovarian cancer	0.000906	0.0235	CbGeAlD
Lapatinib—PI4KB—myometrium—ovarian cancer	0.00089	0.0231	CbGeAlD
Lapatinib—PIK3C2B—endometrium—ovarian cancer	0.00086	0.0223	CbGeAlD
Lapatinib—ERBB2—epithelium—ovarian cancer	0.000746	0.0194	CbGeAlD
Lapatinib—ERBB4—epithelium—ovarian cancer	0.000746	0.0194	CbGeAlD
Lapatinib—TAP1—bone marrow—ovarian cancer	0.000717	0.0186	CbGeAlD
Lapatinib—PIK3C2B—female reproductive system—ovarian cancer	0.000713	0.0185	CbGeAlD
Lapatinib—PIK3C2B—Vindesine—Vinorelbine—ovarian cancer	0.000708	0.418	CbGdCrCtD
Lapatinib—ERBB2—decidua—ovarian cancer	0.000705	0.0183	CbGeAlD
Lapatinib—PI4KB—uterine cervix—ovarian cancer	0.000693	0.018	CbGeAlD
Lapatinib—TAP1—female gonad—ovarian cancer	0.000691	0.0179	CbGeAlD
Lapatinib—TAP1—vagina—ovarian cancer	0.000687	0.0178	CbGeAlD
Lapatinib—PIK3C2B—bone marrow—ovarian cancer	0.000673	0.0175	CbGeAlD
Lapatinib—ERBB2—endometrium—ovarian cancer	0.000669	0.0174	CbGeAlD
Lapatinib—PI4KB—decidua—ovarian cancer	0.00066	0.0171	CbGeAlD
Lapatinib—PIK3C2B—female gonad—ovarian cancer	0.000649	0.0168	CbGeAlD
Lapatinib—PIK3C2B—vagina—ovarian cancer	0.000645	0.0167	CbGeAlD
Lapatinib—EGFR—uterine cervix—ovarian cancer	0.000627	0.0163	CbGeAlD
Lapatinib—PI4KB—endometrium—ovarian cancer	0.000627	0.0163	CbGeAlD
Lapatinib—ERBB2—gonad—ovarian cancer	0.000621	0.0161	CbGeAlD
Lapatinib—ERBB2—uterus—ovarian cancer	0.000617	0.016	CbGeAlD
Lapatinib—TAP1—testis—ovarian cancer	0.000613	0.0159	CbGeAlD
Lapatinib—PI4KB—gonad—ovarian cancer	0.000581	0.0151	CbGeAlD
Lapatinib—PI4KB—uterus—ovarian cancer	0.000578	0.015	CbGeAlD
Lapatinib—PIK3C2B—testis—ovarian cancer	0.000575	0.0149	CbGeAlD
Lapatinib—ERBB2—female reproductive system—ovarian cancer	0.000554	0.0144	CbGeAlD
Lapatinib—ERBB4—female reproductive system—ovarian cancer	0.000554	0.0144	CbGeAlD
Lapatinib—EGFR—uterus—ovarian cancer	0.000523	0.0136	CbGeAlD
Lapatinib—PI4KB—female reproductive system—ovarian cancer	0.000519	0.0135	CbGeAlD
Lapatinib—ERBB2—female gonad—ovarian cancer	0.000504	0.0131	CbGeAlD
Lapatinib—ERBB4—vagina—ovarian cancer	0.000501	0.013	CbGeAlD
Lapatinib—PI4KB—bone marrow—ovarian cancer	0.00049	0.0127	CbGeAlD
Lapatinib—PI4KB—female gonad—ovarian cancer	0.000472	0.0123	CbGeAlD
Lapatinib—PI4KB—vagina—ovarian cancer	0.00047	0.0122	CbGeAlD
Lapatinib—ERBB2—testis—ovarian cancer	0.000447	0.0116	CbGeAlD
Lapatinib—ERBB4—testis—ovarian cancer	0.000447	0.0116	CbGeAlD
Lapatinib—Gefitinib—EGFR—ovarian cancer	0.000444	0.263	CrCbGaD
Lapatinib—TAP1—lymph node—ovarian cancer	0.000444	0.0115	CbGeAlD
Lapatinib—EGFR—female gonad—ovarian cancer	0.000428	0.0111	CbGeAlD
Lapatinib—PI4KB—testis—ovarian cancer	0.000419	0.0109	CbGeAlD
Lapatinib—PIK3C2B—lymph node—ovarian cancer	0.000417	0.0108	CbGeAlD
Lapatinib—PIK3C2B—Vincristine—Vinorelbine—ovarian cancer	0.000382	0.226	CbGdCrCtD
Lapatinib—EGFR—testis—ovarian cancer	0.000379	0.00984	CbGeAlD
Lapatinib—ERBB2—lymph node—ovarian cancer	0.000324	0.00841	CbGeAlD
Lapatinib—PIK3C2B—Vinblastine—Vinorelbine—ovarian cancer	0.000307	0.182	CbGdCrCtD
Lapatinib—PI4KB—lymph node—ovarian cancer	0.000304	0.00788	CbGeAlD
Lapatinib—EGFR—lymph node—ovarian cancer	0.000275	0.00713	CbGeAlD
Lapatinib—CYP2C8—endometrium—ovarian cancer	0.000182	0.00472	CbGeAlD
Lapatinib—CYP3A5—uterine cervix—ovarian cancer	0.000181	0.00471	CbGeAlD
Lapatinib—CYP2C19—vagina—ovarian cancer	0.000156	0.00405	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—ovarian cancer	0.000153	0.0906	CbGdCrCtD
Lapatinib—CYP2C8—female reproductive system—ovarian cancer	0.000151	0.00391	CbGeAlD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—ovarian cancer	0.000142	0.0838	CbGdCrCtD
Lapatinib—CYP2C8—vagina—ovarian cancer	0.000136	0.00353	CbGeAlD
Lapatinib—Gefitinib—ABCB1—ovarian cancer	0.000135	0.0799	CrCbGaD
Lapatinib—ABCB1—myometrium—ovarian cancer	0.000124	0.00321	CbGeAlD
Lapatinib—CYP3A5—female gonad—ovarian cancer	0.000124	0.00321	CbGeAlD
Lapatinib—CYP3A5—vagina—ovarian cancer	0.000123	0.00319	CbGeAlD
Lapatinib—CYP2C8—testis—ovarian cancer	0.000122	0.00315	CbGeAlD
Lapatinib—ABCB1—embryo—ovarian cancer	0.000119	0.00309	CbGeAlD
Lapatinib—CYP3A4—female reproductive system—ovarian cancer	0.000102	0.00265	CbGeAlD
Lapatinib—Decreased appetite—Melphalan—ovarian cancer	9.73e-05	0.00155	CcSEcCtD
Lapatinib—Epistaxis—Paclitaxel—ovarian cancer	9.72e-05	0.00155	CcSEcCtD
Lapatinib—ABCB1—epithelium—ovarian cancer	9.72e-05	0.00252	CbGeAlD
Lapatinib—Infection—Vinorelbine—ovarian cancer	9.71e-05	0.00155	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Melphalan—ovarian cancer	9.66e-05	0.00154	CcSEcCtD
Lapatinib—Fatigue—Melphalan—ovarian cancer	9.65e-05	0.00154	CcSEcCtD
Lapatinib—ABCB1—uterine cervix—ovarian cancer	9.64e-05	0.0025	CbGeAlD
Lapatinib—Nervous system disorder—Vinorelbine—ovarian cancer	9.59e-05	0.00153	CcSEcCtD
Lapatinib—Skin disorder—Vinorelbine—ovarian cancer	9.49e-05	0.00151	CcSEcCtD
Lapatinib—Hypersensitivity—Chlorambucil—ovarian cancer	9.46e-05	0.00151	CcSEcCtD
Lapatinib—Gastrointestinal pain—Topotecan—ovarian cancer	9.34e-05	0.00149	CcSEcCtD
Lapatinib—Anorexia—Vinorelbine—ovarian cancer	9.32e-05	0.00149	CcSEcCtD
Lapatinib—Asthenia—Chlorambucil—ovarian cancer	9.21e-05	0.00147	CcSEcCtD
Lapatinib—ABCB1—decidua—ovarian cancer	9.18e-05	0.00238	CbGeAlD
Lapatinib—Neutropenia—Docetaxel—ovarian cancer	9.16e-05	0.00146	CcSEcCtD
Lapatinib—Connective tissue disorder—Paclitaxel—ovarian cancer	9.09e-05	0.00145	CcSEcCtD
Lapatinib—Pruritus—Chlorambucil—ovarian cancer	9.08e-05	0.00145	CcSEcCtD
Lapatinib—Abdominal pain—Topotecan—ovarian cancer	9.03e-05	0.00144	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	8.91e-05	0.00142	CcSEcCtD
Lapatinib—Pneumonia—Docetaxel—ovarian cancer	8.79e-05	0.0014	CcSEcCtD
Lapatinib—Diarrhoea—Chlorambucil—ovarian cancer	8.78e-05	0.0014	CcSEcCtD
Lapatinib—Infestation—Docetaxel—ovarian cancer	8.74e-05	0.00139	CcSEcCtD
Lapatinib—Infestation NOS—Docetaxel—ovarian cancer	8.74e-05	0.00139	CcSEcCtD
Lapatinib—ABCB1—endometrium—ovarian cancer	8.72e-05	0.00226	CbGeAlD
Lapatinib—Dyspnoea—Vinorelbine—ovarian cancer	8.71e-05	0.00139	CcSEcCtD
Lapatinib—Cardiac disorder—Paclitaxel—ovarian cancer	8.59e-05	0.00137	CcSEcCtD
Lapatinib—Neuropathy peripheral—Docetaxel—ovarian cancer	8.56e-05	0.00137	CcSEcCtD
Lapatinib—Stomatitis—Docetaxel—ovarian cancer	8.52e-05	0.00136	CcSEcCtD
Lapatinib—Decreased appetite—Vinorelbine—ovarian cancer	8.5e-05	0.00136	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	8.44e-05	0.00135	CcSEcCtD
Lapatinib—Fatigue—Vinorelbine—ovarian cancer	8.43e-05	0.00134	CcSEcCtD
Lapatinib—Hypersensitivity—Topotecan—ovarian cancer	8.42e-05	0.00134	CcSEcCtD
Lapatinib—Angiopathy—Paclitaxel—ovarian cancer	8.4e-05	0.00134	CcSEcCtD
Lapatinib—Constipation—Vinorelbine—ovarian cancer	8.36e-05	0.00133	CcSEcCtD
Lapatinib—Immune system disorder—Paclitaxel—ovarian cancer	8.36e-05	0.00133	CcSEcCtD
Lapatinib—Mediastinal disorder—Paclitaxel—ovarian cancer	8.34e-05	0.00133	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—ovarian cancer	8.28e-05	0.00132	CcSEcCtD
Lapatinib—Hepatobiliary disease—Docetaxel—ovarian cancer	8.26e-05	0.00132	CcSEcCtD
Lapatinib—Hypersensitivity—Melphalan—ovarian cancer	8.24e-05	0.00132	CcSEcCtD
Lapatinib—Epistaxis—Docetaxel—ovarian cancer	8.24e-05	0.00131	CcSEcCtD
Lapatinib—Asthenia—Topotecan—ovarian cancer	8.2e-05	0.00131	CcSEcCtD
Lapatinib—Alopecia—Paclitaxel—ovarian cancer	8.18e-05	0.0013	CcSEcCtD
Lapatinib—Hot flush—Epirubicin—ovarian cancer	8.17e-05	0.0013	CcSEcCtD
Lapatinib—Vomiting—Chlorambucil—ovarian cancer	8.16e-05	0.0013	CcSEcCtD
Lapatinib—Mental disorder—Paclitaxel—ovarian cancer	8.11e-05	0.00129	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—ovarian cancer	8.1e-05	0.00129	CcSEcCtD
Lapatinib—ABCB1—gonad—ovarian cancer	8.09e-05	0.0021	CbGeAlD
Lapatinib—Pruritus—Topotecan—ovarian cancer	8.08e-05	0.00129	CcSEcCtD
Lapatinib—Malnutrition—Paclitaxel—ovarian cancer	8.06e-05	0.00129	CcSEcCtD
Lapatinib—ABCB1—uterus—ovarian cancer	8.03e-05	0.00208	CbGeAlD
Lapatinib—Asthenia—Melphalan—ovarian cancer	8.03e-05	0.00128	CcSEcCtD
Lapatinib—Gastrointestinal pain—Vinorelbine—ovarian cancer	7.99e-05	0.00128	CcSEcCtD
Lapatinib—Pruritus—Melphalan—ovarian cancer	7.92e-05	0.00126	CcSEcCtD
Lapatinib—Cardiac failure—Epirubicin—ovarian cancer	7.84e-05	0.00125	CcSEcCtD
Lapatinib—Diarrhoea—Topotecan—ovarian cancer	7.82e-05	0.00125	CcSEcCtD
Lapatinib—Back pain—Paclitaxel—ovarian cancer	7.79e-05	0.00124	CcSEcCtD
Lapatinib—Abdominal pain—Vinorelbine—ovarian cancer	7.73e-05	0.00123	CcSEcCtD
Lapatinib—Connective tissue disorder—Docetaxel—ovarian cancer	7.71e-05	0.00123	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—ovarian cancer	7.66e-05	0.00122	CcSEcCtD
Lapatinib—Diarrhoea—Melphalan—ovarian cancer	7.65e-05	0.00122	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—ovarian cancer	7.65e-05	0.00122	CcSEcCtD
Lapatinib—Nausea—Chlorambucil—ovarian cancer	7.62e-05	0.00122	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—ovarian cancer	7.56e-05	0.00121	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—ovarian cancer	7.5e-05	0.0012	CcSEcCtD
Lapatinib—Anaemia—Paclitaxel—ovarian cancer	7.45e-05	0.00119	CcSEcCtD
Lapatinib—Cardiac disorder—Docetaxel—ovarian cancer	7.28e-05	0.00116	CcSEcCtD
Lapatinib—Vomiting—Topotecan—ovarian cancer	7.26e-05	0.00116	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—ovarian cancer	7.25e-05	0.00116	CcSEcCtD
Lapatinib—ABCB1—female reproductive system—ovarian cancer	7.22e-05	0.00187	CbGeAlD
Lapatinib—Leukopenia—Paclitaxel—ovarian cancer	7.21e-05	0.00115	CcSEcCtD
Lapatinib—Rash—Topotecan—ovarian cancer	7.2e-05	0.00115	CcSEcCtD
Lapatinib—Hypersensitivity—Vinorelbine—ovarian cancer	7.2e-05	0.00115	CcSEcCtD
Lapatinib—Dermatitis—Topotecan—ovarian cancer	7.2e-05	0.00115	CcSEcCtD
Lapatinib—Headache—Topotecan—ovarian cancer	7.16e-05	0.00114	CcSEcCtD
Lapatinib—Palpitations—Paclitaxel—ovarian cancer	7.12e-05	0.00114	CcSEcCtD
Lapatinib—Angiopathy—Docetaxel—ovarian cancer	7.12e-05	0.00114	CcSEcCtD
Lapatinib—Vomiting—Melphalan—ovarian cancer	7.11e-05	0.00113	CcSEcCtD
Lapatinib—Dehydration—Epirubicin—ovarian cancer	7.11e-05	0.00113	CcSEcCtD
Lapatinib—Immune system disorder—Docetaxel—ovarian cancer	7.08e-05	0.00113	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—ovarian cancer	7.08e-05	0.00113	CcSEcCtD
Lapatinib—Mediastinal disorder—Docetaxel—ovarian cancer	7.07e-05	0.00113	CcSEcCtD
Lapatinib—Rash—Melphalan—ovarian cancer	7.05e-05	0.00113	CcSEcCtD
Lapatinib—Dermatitis—Melphalan—ovarian cancer	7.05e-05	0.00112	CcSEcCtD
Lapatinib—Cough—Paclitaxel—ovarian cancer	7.03e-05	0.00112	CcSEcCtD
Lapatinib—Asthenia—Vinorelbine—ovarian cancer	7.01e-05	0.00112	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—ovarian cancer	7.01e-05	0.00112	CcSEcCtD
Lapatinib—Alopecia—Docetaxel—ovarian cancer	6.93e-05	0.00111	CcSEcCtD
Lapatinib—Pruritus—Vinorelbine—ovarian cancer	6.92e-05	0.0011	CcSEcCtD
Lapatinib—Mental disorder—Docetaxel—ovarian cancer	6.87e-05	0.0011	CcSEcCtD
Lapatinib—Arthralgia—Paclitaxel—ovarian cancer	6.86e-05	0.00109	CcSEcCtD
Lapatinib—Myalgia—Paclitaxel—ovarian cancer	6.86e-05	0.00109	CcSEcCtD
Lapatinib—Malnutrition—Docetaxel—ovarian cancer	6.83e-05	0.00109	CcSEcCtD
Lapatinib—ABCB1—bone marrow—ovarian cancer	6.82e-05	0.00177	CbGeAlD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	6.81e-05	0.00109	CcSEcCtD
Lapatinib—Nausea—Topotecan—ovarian cancer	6.79e-05	0.00108	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	6.74e-05	0.00108	CcSEcCtD
Lapatinib—Diarrhoea—Vinorelbine—ovarian cancer	6.69e-05	0.00107	CcSEcCtD
Lapatinib—Nausea—Melphalan—ovarian cancer	6.65e-05	0.00106	CcSEcCtD
Lapatinib—Back pain—Docetaxel—ovarian cancer	6.6e-05	0.00105	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—ovarian cancer	6.58e-05	0.00105	CcSEcCtD
Lapatinib—Anaphylactic shock—Paclitaxel—ovarian cancer	6.57e-05	0.00105	CcSEcCtD
Lapatinib—ABCB1—female gonad—ovarian cancer	6.57e-05	0.0017	CbGeAlD
Lapatinib—Infection—Paclitaxel—ovarian cancer	6.53e-05	0.00104	CcSEcCtD
Lapatinib—ABCB1—vagina—ovarian cancer	6.53e-05	0.00169	CbGeAlD
Lapatinib—Dry skin—Doxorubicin—ovarian cancer	6.49e-05	0.00103	CcSEcCtD
Lapatinib—Nervous system disorder—Paclitaxel—ovarian cancer	6.45e-05	0.00103	CcSEcCtD
Lapatinib—Skin disorder—Paclitaxel—ovarian cancer	6.39e-05	0.00102	CcSEcCtD
Lapatinib—Anaemia—Docetaxel—ovarian cancer	6.31e-05	0.00101	CcSEcCtD
Lapatinib—Anorexia—Paclitaxel—ovarian cancer	6.27e-05	0.001	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	6.24e-05	0.000996	CcSEcCtD
Lapatinib—Vomiting—Vinorelbine—ovarian cancer	6.21e-05	0.000992	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—ovarian cancer	6.18e-05	0.000986	CcSEcCtD
Lapatinib—Rash—Vinorelbine—ovarian cancer	6.16e-05	0.000983	CcSEcCtD
Lapatinib—Dermatitis—Vinorelbine—ovarian cancer	6.16e-05	0.000982	CcSEcCtD
Lapatinib—Headache—Vinorelbine—ovarian cancer	6.12e-05	0.000977	CcSEcCtD
Lapatinib—Leukopenia—Docetaxel—ovarian cancer	6.11e-05	0.000975	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—ovarian cancer	6.03e-05	0.000963	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	5.99e-05	0.000956	CcSEcCtD
Lapatinib—Cough—Docetaxel—ovarian cancer	5.96e-05	0.000951	CcSEcCtD
Lapatinib—Insomnia—Paclitaxel—ovarian cancer	5.95e-05	0.000949	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—ovarian cancer	5.93e-05	0.000946	CcSEcCtD
Lapatinib—Infestation—Epirubicin—ovarian cancer	5.89e-05	0.00094	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—ovarian cancer	5.89e-05	0.00094	CcSEcCtD
Lapatinib—Dyspnoea—Paclitaxel—ovarian cancer	5.86e-05	0.000935	CcSEcCtD
Lapatinib—ABCB1—testis—ovarian cancer	5.83e-05	0.00151	CbGeAlD
Lapatinib—Arthralgia—Docetaxel—ovarian cancer	5.81e-05	0.000927	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—ovarian cancer	5.81e-05	0.000927	CcSEcCtD
Lapatinib—Nausea—Vinorelbine—ovarian cancer	5.81e-05	0.000926	CcSEcCtD
Lapatinib—Dyspepsia—Paclitaxel—ovarian cancer	5.79e-05	0.000923	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—ovarian cancer	5.78e-05	0.000922	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	5.77e-05	0.000921	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—ovarian cancer	5.74e-05	0.000917	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—ovarian cancer	5.72e-05	0.000912	CcSEcCtD
Lapatinib—Decreased appetite—Paclitaxel—ovarian cancer	5.72e-05	0.000912	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	5.68e-05	0.000906	CcSEcCtD
Lapatinib—Fatigue—Paclitaxel—ovarian cancer	5.67e-05	0.000904	CcSEcCtD
Lapatinib—Constipation—Paclitaxel—ovarian cancer	5.62e-05	0.000897	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—ovarian cancer	5.57e-05	0.000889	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—ovarian cancer	5.57e-05	0.000889	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—ovarian cancer	5.56e-05	0.000887	CcSEcCtD
Lapatinib—Infection—Docetaxel—ovarian cancer	5.54e-05	0.000883	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—ovarian cancer	5.48e-05	0.000875	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—ovarian cancer	5.46e-05	0.000872	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—ovarian cancer	5.45e-05	0.00087	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—ovarian cancer	5.45e-05	0.00087	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—ovarian cancer	5.41e-05	0.000864	CcSEcCtD
Lapatinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.38e-05	0.000858	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	5.35e-05	0.000853	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—ovarian cancer	5.32e-05	0.000848	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—ovarian cancer	5.31e-05	0.000848	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—ovarian cancer	5.2e-05	0.000829	CcSEcCtD
Lapatinib—Abdominal pain—Paclitaxel—ovarian cancer	5.2e-05	0.000829	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.16e-05	0.000823	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—ovarian cancer	5.14e-05	0.000821	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.08e-05	0.00081	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—ovarian cancer	5.04e-05	0.000804	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—ovarian cancer	4.97e-05	0.000793	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—ovarian cancer	4.91e-05	0.000783	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—ovarian cancer	4.91e-05	0.000783	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—ovarian cancer	4.84e-05	0.000773	CcSEcCtD
Lapatinib—Hypersensitivity—Paclitaxel—ovarian cancer	4.84e-05	0.000773	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	4.81e-05	0.000768	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—ovarian cancer	4.81e-05	0.000768	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—ovarian cancer	4.8e-05	0.000767	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—ovarian cancer	4.8e-05	0.000766	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—ovarian cancer	4.78e-05	0.000762	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—ovarian cancer	4.77e-05	0.000761	CcSEcCtD
Lapatinib—Constipation—Docetaxel—ovarian cancer	4.77e-05	0.00076	CcSEcCtD
Lapatinib—Asthenia—Paclitaxel—ovarian cancer	4.72e-05	0.000753	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—ovarian cancer	4.67e-05	0.000746	CcSEcCtD
Lapatinib—Pruritus—Paclitaxel—ovarian cancer	4.65e-05	0.000742	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—ovarian cancer	4.63e-05	0.00074	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—ovarian cancer	4.61e-05	0.000735	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—ovarian cancer	4.56e-05	0.000727	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—ovarian cancer	4.54e-05	0.000725	CcSEcCtD
Lapatinib—Diarrhoea—Paclitaxel—ovarian cancer	4.5e-05	0.000718	CcSEcCtD
Lapatinib—Back pain—Epirubicin—ovarian cancer	4.45e-05	0.000711	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—ovarian cancer	4.44e-05	0.000709	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—ovarian cancer	4.42e-05	0.000705	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—ovarian cancer	4.41e-05	0.000704	CcSEcCtD
Lapatinib—Abdominal pain—Docetaxel—ovarian cancer	4.41e-05	0.000703	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—ovarian cancer	4.33e-05	0.00069	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—ovarian cancer	4.29e-05	0.000684	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—ovarian cancer	4.26e-05	0.00068	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—ovarian cancer	4.26e-05	0.000679	CcSEcCtD
Lapatinib—ABCB1—lymph node—ovarian cancer	4.22e-05	0.0011	CbGeAlD
Lapatinib—Vomiting—Paclitaxel—ovarian cancer	4.18e-05	0.000667	CcSEcCtD
Lapatinib—Rash—Paclitaxel—ovarian cancer	4.15e-05	0.000661	CcSEcCtD
Lapatinib—Dermatitis—Paclitaxel—ovarian cancer	4.14e-05	0.000661	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—ovarian cancer	4.12e-05	0.000658	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—ovarian cancer	4.12e-05	0.000658	CcSEcCtD
Lapatinib—Headache—Paclitaxel—ovarian cancer	4.12e-05	0.000657	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—ovarian cancer	4.11e-05	0.000655	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—ovarian cancer	4.07e-05	0.000649	CcSEcCtD
Lapatinib—Cough—Epirubicin—ovarian cancer	4.02e-05	0.000641	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—ovarian cancer	4e-05	0.000638	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—ovarian cancer	3.94e-05	0.000629	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—ovarian cancer	3.94e-05	0.000628	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—ovarian cancer	3.92e-05	0.000626	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—ovarian cancer	3.92e-05	0.000626	CcSEcCtD
Lapatinib—Nausea—Paclitaxel—ovarian cancer	3.91e-05	0.000623	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.89e-05	0.000621	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—ovarian cancer	3.81e-05	0.000609	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—ovarian cancer	3.81e-05	0.000608	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—ovarian cancer	3.77e-05	0.000601	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—ovarian cancer	3.76e-05	0.0006	CcSEcCtD
Lapatinib—Infection—Epirubicin—ovarian cancer	3.73e-05	0.000596	CcSEcCtD
Lapatinib—Cough—Doxorubicin—ovarian cancer	3.72e-05	0.000593	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—ovarian cancer	3.69e-05	0.000588	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—ovarian cancer	3.65e-05	0.000583	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—ovarian cancer	3.63e-05	0.000579	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—ovarian cancer	3.63e-05	0.000579	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.6e-05	0.000575	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—ovarian cancer	3.58e-05	0.000572	CcSEcCtD
Lapatinib—Vomiting—Docetaxel—ovarian cancer	3.54e-05	0.000565	CcSEcCtD
Lapatinib—Rash—Docetaxel—ovarian cancer	3.51e-05	0.000561	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—ovarian cancer	3.51e-05	0.00056	CcSEcCtD
Lapatinib—Headache—Docetaxel—ovarian cancer	3.49e-05	0.000557	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—ovarian cancer	3.48e-05	0.000555	CcSEcCtD
Lapatinib—Infection—Doxorubicin—ovarian cancer	3.46e-05	0.000551	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.42e-05	0.000546	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—ovarian cancer	3.41e-05	0.000544	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—ovarian cancer	3.4e-05	0.000542	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—ovarian cancer	3.38e-05	0.000539	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—ovarian cancer	3.35e-05	0.000535	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—ovarian cancer	3.32e-05	0.000529	CcSEcCtD
Lapatinib—Nausea—Docetaxel—ovarian cancer	3.31e-05	0.000528	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—ovarian cancer	3.31e-05	0.000528	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—ovarian cancer	3.27e-05	0.000521	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.24e-05	0.000518	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—ovarian cancer	3.24e-05	0.000517	CcSEcCtD
Lapatinib—Constipation—Epirubicin—ovarian cancer	3.21e-05	0.000513	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.17e-05	0.000506	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—ovarian cancer	3.15e-05	0.000502	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—ovarian cancer	3.1e-05	0.000495	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—ovarian cancer	3.07e-05	0.00049	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—ovarian cancer	3.06e-05	0.000488	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—ovarian cancer	3.02e-05	0.000482	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3e-05	0.000479	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—ovarian cancer	3e-05	0.000478	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—ovarian cancer	2.97e-05	0.000475	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—ovarian cancer	2.97e-05	0.000474	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.84e-05	0.000454	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—ovarian cancer	2.77e-05	0.000442	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—ovarian cancer	2.75e-05	0.000439	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—ovarian cancer	2.7e-05	0.00043	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—ovarian cancer	2.66e-05	0.000424	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—ovarian cancer	2.57e-05	0.00041	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—ovarian cancer	2.56e-05	0.000409	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—ovarian cancer	2.5e-05	0.000398	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—ovarian cancer	2.46e-05	0.000393	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—ovarian cancer	2.39e-05	0.000381	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—ovarian cancer	2.38e-05	0.00038	CcSEcCtD
Lapatinib—Rash—Epirubicin—ovarian cancer	2.37e-05	0.000378	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—ovarian cancer	2.37e-05	0.000378	CcSEcCtD
Lapatinib—Headache—Epirubicin—ovarian cancer	2.35e-05	0.000376	CcSEcCtD
Lapatinib—Nausea—Epirubicin—ovarian cancer	2.23e-05	0.000356	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—ovarian cancer	2.21e-05	0.000353	CcSEcCtD
Lapatinib—Rash—Doxorubicin—ovarian cancer	2.19e-05	0.00035	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—ovarian cancer	2.19e-05	0.00035	CcSEcCtD
Lapatinib—Headache—Doxorubicin—ovarian cancer	2.18e-05	0.000348	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—ovarian cancer	2.07e-05	0.00033	CcSEcCtD
Lapatinib—EGFR—Disease—CAV1—ovarian cancer	3.03e-06	4.5e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MAPK1—ovarian cancer	3.03e-06	4.5e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—EGFR—ovarian cancer	3.03e-06	4.5e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MTOR—ovarian cancer	3.02e-06	4.48e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CB—ovarian cancer	3.02e-06	4.48e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.01e-06	4.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—KRAS—ovarian cancer	2.96e-06	4.39e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.95e-06	4.38e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CXCL8—ovarian cancer	2.95e-06	4.37e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.93e-06	4.35e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NRAS—ovarian cancer	2.91e-06	4.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MAPK3—ovarian cancer	2.91e-06	4.31e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KRAS—ovarian cancer	2.91e-06	4.31e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CXCL8—ovarian cancer	2.9e-06	4.31e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—PIK3CA—ovarian cancer	2.89e-06	4.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PPP2R1A—ovarian cancer	2.89e-06	4.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CD—ovarian cancer	2.88e-06	4.27e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CDKN1B—ovarian cancer	2.88e-06	4.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6ST—ovarian cancer	2.88e-06	4.27e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—FASN—ovarian cancer	2.86e-06	4.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KRAS—ovarian cancer	2.86e-06	4.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—PIK3CA—ovarian cancer	2.85e-06	4.23e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.84e-06	4.21e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CDKN1B—ovarian cancer	2.83e-06	4.21e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CASP3—ovarian cancer	2.82e-06	4.18e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL2—ovarian cancer	2.82e-06	4.18e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SLC5A5—ovarian cancer	2.82e-06	4.18e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYTB—ovarian cancer	2.78e-06	4.13e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CASP3—ovarian cancer	2.78e-06	4.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL2—ovarian cancer	2.77e-06	4.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MAPK1—ovarian cancer	2.77e-06	4.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—APC—ovarian cancer	2.76e-06	4.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDH1—ovarian cancer	2.75e-06	4.09e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCND1—ovarian cancer	2.75e-06	4.07e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SLC2A1—ovarian cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CTNNB1—ovarian cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—YAP1—ovarian cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCND1—ovarian cancer	2.7e-06	4.01e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.69e-06	3.99e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CTNNB1—ovarian cancer	2.68e-06	3.97e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HRAS—ovarian cancer	2.68e-06	3.97e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PIK3CA—ovarian cancer	2.67e-06	3.96e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—ovarian cancer	2.67e-06	3.95e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTEN—ovarian cancer	2.65e-06	3.93e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—YAP1—ovarian cancer	2.65e-06	3.93e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.65e-06	3.93e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HRAS—ovarian cancer	2.64e-06	3.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CD—ovarian cancer	2.63e-06	3.9e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PIK3CA—ovarian cancer	2.63e-06	3.9e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—ovarian cancer	2.63e-06	3.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KRAS—ovarian cancer	2.61e-06	3.88e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTEN—ovarian cancer	2.61e-06	3.87e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP1B1—ovarian cancer	2.61e-06	3.87e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—ovarian cancer	2.56e-06	3.8e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—ovarian cancer	2.52e-06	3.74e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—HRAS—ovarian cancer	2.51e-06	3.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CB—ovarian cancer	2.51e-06	3.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KRAS—ovarian cancer	2.51e-06	3.72e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—FASN—ovarian cancer	2.48e-06	3.68e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—ovarian cancer	2.47e-06	3.66e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC5A5—ovarian cancer	2.44e-06	3.62e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.43e-06	3.61e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.43e-06	3.61e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—ovarian cancer	2.43e-06	3.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CD—ovarian cancer	2.43e-06	3.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL8—ovarian cancer	2.41e-06	3.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—ovarian cancer	2.41e-06	3.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PIK3CA—ovarian cancer	2.4e-06	3.56e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.4e-06	3.56e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—ovarian cancer	2.39e-06	3.55e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—ovarian cancer	2.37e-06	3.52e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—ovarian cancer	2.36e-06	3.51e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—ovarian cancer	2.36e-06	3.51e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—ovarian cancer	2.36e-06	3.5e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.36e-06	3.5e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—ovarian cancer	2.36e-06	3.5e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC2A1—ovarian cancer	2.36e-06	3.49e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—ovarian cancer	2.33e-06	3.46e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—ovarian cancer	2.33e-06	3.45e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—ovarian cancer	2.33e-06	3.45e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—ovarian cancer	2.33e-06	3.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ERBB2—ovarian cancer	2.32e-06	3.45e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	2.31e-06	3.43e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.31e-06	3.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL2—ovarian cancer	2.3e-06	3.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PIK3CA—ovarian cancer	2.3e-06	3.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TERT—ovarian cancer	2.3e-06	3.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CB—ovarian cancer	2.29e-06	3.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MTOR—ovarian cancer	2.29e-06	3.4e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK3—ovarian cancer	2.26e-06	3.36e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1B1—ovarian cancer	2.26e-06	3.35e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK3—ovarian cancer	2.23e-06	3.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—ovarian cancer	2.22e-06	3.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—ovarian cancer	2.22e-06	3.29e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—FASN—ovarian cancer	2.21e-06	3.28e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—ovarian cancer	2.2e-06	3.27e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—ovarian cancer	2.18e-06	3.24e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.18e-06	3.23e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—ovarian cancer	2.17e-06	3.22e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—FASN—ovarian cancer	2.16e-06	3.2e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK1—ovarian cancer	2.15e-06	3.2e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EGFR—ovarian cancer	2.15e-06	3.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1B—ovarian cancer	2.15e-06	3.19e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—ovarian cancer	2.15e-06	3.19e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ABCB1—ovarian cancer	2.15e-06	3.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—ERBB2—ovarian cancer	2.15e-06	3.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—ovarian cancer	2.13e-06	3.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—ovarian cancer	2.13e-06	3.15e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC5A5—ovarian cancer	2.12e-06	3.15e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CAV1—ovarian cancer	2.12e-06	3.15e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK1—ovarian cancer	2.12e-06	3.15e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EGFR—ovarian cancer	2.12e-06	3.15e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MTOR—ovarian cancer	2.12e-06	3.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CB—ovarian cancer	2.12e-06	3.14e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TYMS—ovarian cancer	2.11e-06	3.13e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2—ovarian cancer	2.11e-06	3.12e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.1e-06	3.12e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.06e-06	3.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC2A1—ovarian cancer	2.05e-06	3.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ESR1—ovarian cancer	2.05e-06	3.04e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—ovarian cancer	2.03e-06	3.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTNNB1—ovarian cancer	2.03e-06	3.02e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.02e-06	2.99e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6ST—ovarian cancer	2.01e-06	2.99e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—ovarian cancer	2e-06	2.97e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	2e-06	2.97e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.99e-06	2.96e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1B—ovarian cancer	1.99e-06	2.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—ovarian cancer	1.98e-06	2.94e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.97e-06	2.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—ovarian cancer	1.96e-06	2.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APC—ovarian cancer	1.93e-06	2.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—ovarian cancer	1.93e-06	2.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—ovarian cancer	1.93e-06	2.87e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—ovarian cancer	1.88e-06	2.79e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CTNNB1—ovarian cancer	1.88e-06	2.78e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—ovarian cancer	1.87e-06	2.77e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCB1—ovarian cancer	1.86e-06	2.76e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK3—ovarian cancer	1.85e-06	2.75e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—ovarian cancer	1.84e-06	2.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—ovarian cancer	1.83e-06	2.71e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TYMS—ovarian cancer	1.83e-06	2.71e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—ovarian cancer	1.81e-06	2.68e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.79e-06	2.65e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—ovarian cancer	1.78e-06	2.64e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.78e-06	2.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—ovarian cancer	1.77e-06	2.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—ovarian cancer	1.77e-06	2.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK1—ovarian cancer	1.76e-06	2.62e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.74e-06	2.59e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—ovarian cancer	1.73e-06	2.57e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—ovarian cancer	1.7e-06	2.53e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CD—ovarian cancer	1.7e-06	2.52e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CAV1—ovarian cancer	1.7e-06	2.52e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK3—ovarian cancer	1.69e-06	2.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—ovarian cancer	1.67e-06	2.47e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.66e-06	2.46e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—ovarian cancer	1.66e-06	2.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—ovarian cancer	1.64e-06	2.43e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—YAP1—ovarian cancer	1.63e-06	2.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—ovarian cancer	1.63e-06	2.42e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—ovarian cancer	1.63e-06	2.42e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TYMS—ovarian cancer	1.63e-06	2.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK1—ovarian cancer	1.61e-06	2.39e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TYMS—ovarian cancer	1.59e-06	2.36e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK3—ovarian cancer	1.56e-06	2.32e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	1.55e-06	2.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	1.53e-06	2.27e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—ovarian cancer	1.53e-06	2.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—ovarian cancer	1.52e-06	2.26e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—ovarian cancer	1.52e-06	2.26e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—ovarian cancer	1.5e-06	2.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—ovarian cancer	1.5e-06	2.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK1—ovarian cancer	1.49e-06	2.21e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MTOR—ovarian cancer	1.48e-06	2.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	1.48e-06	2.2e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CAV1—ovarian cancer	1.47e-06	2.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	1.42e-06	2.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	1.42e-06	2.1e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.41e-06	2.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—ovarian cancer	1.4e-06	2.08e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—ovarian cancer	1.4e-06	2.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.39e-06	2.06e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—ovarian cancer	1.36e-06	2.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—ovarian cancer	1.36e-06	2.02e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.36e-06	2.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—ovarian cancer	1.35e-06	2.01e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.34e-06	1.99e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—FASN—ovarian cancer	1.33e-06	1.97e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—ovarian cancer	1.33e-06	1.97e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.31e-06	1.95e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CAV1—ovarian cancer	1.31e-06	1.95e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.31e-06	1.94e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—ovarian cancer	1.29e-06	1.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—ovarian cancer	1.29e-06	1.91e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—ovarian cancer	1.29e-06	1.91e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.28e-06	1.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—ovarian cancer	1.28e-06	1.9e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.26e-06	1.88e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.26e-06	1.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	1.25e-06	1.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—ovarian cancer	1.24e-06	1.84e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.21e-06	1.8e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.2e-06	1.78e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—ovarian cancer	1.19e-06	1.77e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.19e-06	1.76e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.18e-06	1.75e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.17e-06	1.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	1.16e-06	1.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—ovarian cancer	1.15e-06	1.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—ovarian cancer	1.14e-06	1.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—ovarian cancer	1.14e-06	1.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—ovarian cancer	1.14e-06	1.69e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	1.09e-06	1.62e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.08e-06	1.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—ovarian cancer	1.06e-06	1.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—ovarian cancer	1.05e-06	1.56e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.05e-06	1.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	1.04e-06	1.55e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.03e-06	1.52e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.03e-06	1.52e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—ovarian cancer	1.02e-06	1.52e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	9.98e-07	1.48e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—ovarian cancer	9.84e-07	1.46e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMS—ovarian cancer	9.8e-07	1.45e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CB—ovarian cancer	9.17e-07	1.36e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	9.04e-07	1.34e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	8.95e-07	1.33e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—ovarian cancer	8.88e-07	1.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—ovarian cancer	8.74e-07	1.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—ovarian cancer	8.36e-07	1.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—ovarian cancer	8e-07	1.19e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—ovarian cancer	7.92e-07	1.18e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CAV1—ovarian cancer	7.9e-07	1.17e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—ovarian cancer	7.73e-07	1.15e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—ovarian cancer	7.38e-07	1.1e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	7.23e-07	1.07e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	7.2e-07	1.07e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	6.33e-07	9.38e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	6.26e-07	9.29e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—ovarian cancer	5.91e-07	8.76e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—ovarian cancer	5.59e-07	8.29e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.51e-07	8.18e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	5.46e-07	8.09e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—ovarian cancer	5.12e-07	7.59e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—ovarian cancer	4.76e-07	7.07e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—ovarian cancer	4.57e-07	6.77e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—ovarian cancer	4.46e-07	6.61e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.36e-07	4.99e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—ovarian cancer	2.75e-07	4.07e-06	CbGpPWpGaD
